CMS Open Payments · Tool
GC Biopharma USA, Inc. vs Novo Nordisk US Research & Development, Inc.
Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.
A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.
Compare Different Companies
Relationship comparison
Which recorded payment profile is more concentrated?
Novo Nordisk US Research & Development, Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 5,774, versus 3,791 for the other company. Its single largest recorded recipient represents 69.8% of that company's General Payments recipient total.
HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.
- GC Biopharma USA, Inc.
- HHI 3,791 · top recipient 61.5%
- Ranked #467 of 1,838 companies by HHI
- Novo Nordisk US Research & Development, Inc.
- HHI 5,774 · top recipient 69.8%
- Ranked #277 of 1,838 companies by HHI
Payment Overview
GC Biopharma USA, Inc.
- Total Payments
- $8.1K
- % of Industry
- 0.0%
- Transactions
- 158
- Avg per Transaction
- $51.48
- Recipients
- 158
- Avg per Recipient
- $51.48
- Payment Types
- 1
- Top Payment Type
- Food and Beverage
- Total Payments
- $7.8K
- % of Industry
- 0.0%
- Transactions
- 3
- Avg per Transaction
- $2.6K
- Recipients
- 3
- Avg per Recipient
- $2.6K
- Payment Types
- 2
- Top Payment Type
- Consulting Fee
Highlighted values indicate the higher figure for each metric.
Total payments compared
GC Biopharma USA, Inc. vs Novo Nordisk US Research & Development, Inc. - total reported payments in CMS Open Payments PY2024
General Payment Types Breakdown
Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.
GC Biopharma USA, Inc.
100.0%
Novo Nordisk US Research & Development, Inc.
99.8%
0.2%
Top 5 General-Payment Recipients
This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.
GC Biopharma USA, Inc.
- 1
Raffi Tachdjian
$5,000.00 · 1 txns
- 2
TODD HRABAK
$57.85 · 3 txns
- 3
MICHAEL POLCARI
$45.22 · 2 txns
- 4
DUANE WONG
$42.78 · 3 txns
- 5
Ryan CASPER
$41.81 · 2 txns
Novo Nordisk US Research & Development, Inc.
- 1
LUIGI ADAMO
$5,425.00 · 1 txns
- 2
JONATHAN S WILENSKY
$2,325.00 · 1 txns
- 3
JONATHAN G STINE
$17.41 · 1 txns
Summary Comparison
| Metric | GC Biopharma USA, Inc. | Novo Nordisk US Research & Development, Inc. |
|---|---|---|
| Total Payments | $8.1K | $7.8K |
| % of Industry Total | 0.0% | 0.0% |
| Transaction Count | 158 | 3 |
| Avg per Transaction | $51.48 | $2.6K |
| Recipient Count | 158 | 3 |
| Avg per Recipient | $51.48 | $2.6K |
| Payment Type Count | 1 | 2 |
| Top Payment Type | Food and Beverage | Consulting Fee |
Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.